Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years

Trial Profile

A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs VLA 1553 (Primary)
  • Indications Chikungunya virus infections
  • Focus Adverse reactions
  • Sponsors Valneva
  • Most Recent Events

    • 07 Jan 2019 According to a Valneva media release, phase 1 revaccination data post month six and unblinded safety and immunogenicity data at dose group level is expected by mid-year 2019.
    • 07 Jan 2019 Interim results including blinded, pooled safety and immunogenicity data up to Day 28 were presented in a Valneva media release.
    • 21 Dec 2018 According to a Valneva media release, the company will release initial data from he study in coming weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top